Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

2.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist UH, Blimark C, Turesson I.

Eur J Haematol. 2017 Sep;99(3):216-222. doi: 10.1111/ejh.12907. Epub 2017 Jun 28.

PMID:
28544116
3.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.

Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee.

Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.

PMID:
25621805
4.

Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.

Norin S, Björkstrand B, Rommel F, Timberg L, Andersson PO, Häggström J, Aldrin A, Hansson L.

Leuk Res. 2015 Jan;39(1):33-7. doi: 10.1016/j.leukres.2014.09.019. Epub 2014 Nov 13.

PMID:
25499233
5.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.

6.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
21730266
7.

Efficacy and outcome of autologous transplantation in rare myelomas.

Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, Niederwieser D, Gahrton G; Myeloma Subcommittee of Chronic Leukaemia Working Party of EBMT.

Haematologica. 2010 Dec;95(12):2126-33. doi: 10.3324/haematol.2010.022848. Epub 2010 Oct 22.

8.

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.

Johnsen HE, Bøgsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, Nielsen JL, Björkstrand B, Gruber A, Lenhoff S, Remes K, Dahl IM, Fogd K, Dybkaer K; Nordic Myeloma Study (NMSG); Myeloma Stem Cell Network (MSCNET).

Cytometry B Clin Cytom. 2010 Sep;78(5):338-47. doi: 10.1002/cyto.b.20523. Epub 2010 Apr 28.

9.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group.

Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

10.

Primary plasma cell leukemia and autologous stem cell transplantation.

Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, Björkstrand B, Gahrton G; European Group for Blood and Marrow Transplantation and the European Leukemia Net.

Haematologica. 2010 May;95(5):804-9. doi: 10.3324/haematol.2009.013334.

11.

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.

Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom A, Gahrton G, Nahi H.

Oncol Rep. 2009 Jul;22(1):137-42.

PMID:
19513515
12.

Allogeneic transplantation in multiple myeloma.

Gahrton G, Björkstrand B.

Haematologica. 2008 Sep;93(9):1295-300. doi: 10.3324/haematol.13555. No abstract available.

13.

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Björkstrand B, Arteaga HJ, Nore BF, Smith CI.

Blood. 2008 May 1;111(9):4617-26. doi: 10.1182/blood-2007-10-121137. Epub 2008 Feb 21.

14.

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.

Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS.

Blood. 2008 Mar 15;111(6):3155-62. doi: 10.1182/blood-2007-09-110312. Epub 2008 Jan 11.

15.

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.

Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D; Myeloma Subcommittee of the EBMT.

Haematologica. 2007 Nov;92(11):1513-8.

16.

High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.

Björkstrand B, Gahrton G.

Semin Hematol. 2007 Oct;44(4):227-33. Review.

PMID:
17961721
17.

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.

Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, Salles G, Feremans W, Apperley J, Samson D, Björkstrand B, Niederwieser D, Gahrton G, Pico JL, Goldschmidt H; European Group for Blood and Marrow Transplantation.

Haematologica. 2007 Aug;92(8):1083-90. Epub 2007 Jul 20.

18.

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.

Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G.

Blood. 2007 Apr 15;109(8):3588-94. Epub 2006 Dec 7.

19.

Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.

Alici E, Björkstrand B, Treschow A, Aints A, Smith CI, Gahrton G, Dilber MS.

Cancer Gene Ther. 2007 Mar;14(3):227-32. Epub 2006 Nov 3.

PMID:
17082794
20.

Role of stem cell transplantation in myeloma.

Gahrton G, Iacobelli S, Björkstrand B, Bourhis J, Corradini P, Crawley C, Morris C, Niederwieser D; European Group for Blood and Marrow Transplantation.

Hematology. 2005;10 Suppl 1:127-8. Review. No abstract available.

PMID:
16276618
21.

Stem cell transplantation in multiple myeloma.

Björkstrand B.

Hematology. 2005;10 Suppl 1:26-8. Review. No abstract available.

PMID:
16188627
22.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Björkstrand B, Niederwieser D, Gahrton G, Apperley JF; Chromic Leukaemia Working Party of the EBMT.

Blood. 2005 Jun 1;105(11):4532-9. Epub 2005 Feb 24.

23.

The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants.

Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D.

Bone Marrow Transplant. 2005 Mar;35(6):609-17.

PMID:
15696179
24.

Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study.

Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, Gahrton G; Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation.

J Clin Oncol. 2004 May 1;22(9):1674-81. Epub 2004 Mar 22.

PMID:
15037597
25.

Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.

Lundin J, Osterborg A, Björkholm M, Björkstrand B, Celsing F, Hjalmar V, Linder O, Luthman M, Merup M, Tidefelt U, Mellstedt H; Myeloma Group of Central Sweden.

Hematol J. 2003;4(4):248-52.

PMID:
12872149
26.

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.

Björkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE.

Eur J Haematol. 2003 Jun;70(6):379-83.

PMID:
12756020
27.

Symptom distress, functional status and health-related quality of life before high-dose chemotherapy with stem-cell transplantation.

Larsen J, Nordström G, Björkstrand B, Ljungman P, Gardulf A.

Eur J Cancer Care (Engl). 2003 Mar;12(1):71-80.

PMID:
12641559
28.

Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.

Rasmussen T, Björkstrand B, Andersen H, Gaarsdal E, Johnsen HE.

Exp Hematol. 2002 Jan;30(1):82-8.

PMID:
11823041
29.

European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma.

Björkstrand B.

Semin Hematol. 2001 Jul;38(3):219-25. Review.

PMID:
11486309
30.

Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.

Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Bladé J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L; European Group for Blood and Marrow Transplantation.

Br J Haematol. 2001 Apr;113(1):209-16.

PMID:
11360893
31.

Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).

Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.

Bone Marrow Transplant. 2001 Mar;27(5):511-5.

32.

High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD.

Lindahl J, Kimby E, Björkstrand B, Christensson B, Hellström-Lindberg E.

Leuk Res. 2001 Mar;25(3):267-70.

PMID:
11226525
33.

Progress in haematopoietic stem cell transplantation for multiple myeloma.

Gahrton G, Björkstrand B.

J Intern Med. 2000 Sep;248(3):185-201. Review.

34.
35.

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Hassan M, Svensson US, Ljungman P, Björkstrand B, Olsson H, Bielenstein M, Abdel-Rehim M, Nilsson C, Johansson M, Karlsson MO.

Br J Clin Pharmacol. 1999 Nov;48(5):669-77.

36.

Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.

Gahrton G, Svensson H, Björkstrand B, Apperley J, Carlson K, Cavo M, Ferrant A, Fouillard L, Gratecos N, Gratwohl A, Guilhot F, Lambertenghi Deliliers G, Ljungman P, Masszi T, Milligan DW, Powles RL, Reiffers J, Samson JD, Stoppa AM, Vernant JP, Volin L, Wallvik J.

Bone Marrow Transplant. 1999 Oct;24(7):741-5.

37.

Unrelated donor stem cell transplantation after autologous transplantation: experience of a single center.

Aschan J, Remberger M, Carlens S, Mattsson J, Dilber MS, Lönnqvist B, Björkstrand B.

Bone Marrow Transplant. 1999 Aug;24(3):279-82.

38.

High-dose treatment of multiple myeloma.

Gahrton G, Björkstrand B.

Crit Rev Oncol Hematol. 1999 Apr;30(2):173-80. Review. No abstract available.

PMID:
10439061
39.

A controlled comparison of two different clinical grade devices for CD34+ cell selection of autologous blood stem cell grafts.

Björkstrand B, Sundman-Engberg B, Christensson B, Kumlien G.

J Hematother. 1999 Feb;8(1):75-80.

PMID:
10192304
40.

Gene marking and gene therapy in multiple myeloma.

Gahrton G, Björkstrand B, Dilber MS, Sundman-Engberg B, Ljungman P, Smith CI.

Adv Exp Med Biol. 1998;451:493-7. Review. No abstract available.

PMID:
10026917
41.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D.

Br J Haematol. 1998 Sep;102(5):1115-23. No abstract available.

PMID:
9753033
42.

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer.

Ljungman P, Björkstrand B, Fornander T, Höglund M, Juliusson G, Lindman H, Malmström A, Rotstein S, Söderberg M, Wilking N, Villman K, Bergh J.

Bone Marrow Transplant. 1998 Sep;22(5):445-8.

44.

Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients.

Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Oberg G, Ljungman P.

Bone Marrow Transplant. 1998 Jul;22(1):67-71.

45.

Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study.

Ljungman P, Hägglund H, Björkstrand B, Lönnqvist B, Ringdén O.

Support Care Cancer. 1997 Nov;5(6):485-8.

PMID:
9406362
46.

Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo.

Dilber MS, Abedi MR, Christensson B, Björkstrand B, Kidder GM, Naus CC, Gahrton G, Smith CI.

Cancer Res. 1997 Apr 15;57(8):1523-8.

47.

Radiography and bone scintigraphy in bone marrow transplant multiple myeloma patients.

Agren B, Lönnqvist B, Björkstrand B, Rudberg U, Aspelin P.

Acta Radiol. 1997 Jan;38(1):144-50.

PMID:
9059419
48.

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.

Björkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Bladé J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G.

Blood. 1996 Dec 15;88(12):4711-8.

49.

Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support.

Johnsen HE, Björkstrand B, Carlson K, Gruber A, Blystad A, Fast A, Boesen AM, Björkholm M, Sallerfors B, Ruutu T, Carneskog J, Malm A, Geisler C, Lehtinen M, Schrøder H, Brinch L, Remes K, Tidefelt U, Heilmann C, Hörnsten P, Thorling K, Daugaard G.

Leuk Lymphoma. 1996 Dec;24(1-2):81-91.

PMID:
9049964
50.

Health-related quality of life in women with breast cancer undergoing autologous stem-cell transplantation.

Larsen J, Gardulf A, Nordström G, Björkstrand B, Ljungman P.

Cancer Nurs. 1996 Oct;19(5):368-75.

PMID:
8885485

Supplemental Content

Loading ...
Support Center